Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 681257 DDI with Warfarin in Healthy Subjects
NCT03426033Phase 1Completed
- Sponsor
- Akcea Therapeutics
- Start
- Dec 2017
- Primary completion
- Feb 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of pelacarsen in Hyperlipoproteinemia a and cardiovascular diseases (CVD) (2 arms), sponsored by Akcea Therapeutics. Primary endpoint: Plasma concentrations of warfarin and ISIS 681257. Started Dec 2017; status: completed.
02
Drugs
pelacarsen
03
Conditions
Hyperlipoproteinemia acardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT03426033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426033.